WO2008131586A1 - Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents - Google Patents
Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents Download PDFInfo
- Publication number
- WO2008131586A1 WO2008131586A1 PCT/CN2007/001423 CN2007001423W WO2008131586A1 WO 2008131586 A1 WO2008131586 A1 WO 2008131586A1 CN 2007001423 W CN2007001423 W CN 2007001423W WO 2008131586 A1 WO2008131586 A1 WO 2008131586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- pyridone
- tnf
- group
- alkyl group
- Prior art date
Links
- -1 5-methyl-1-(substituted phenyl)-2(1h)-pyridones Chemical class 0.000 title claims abstract description 29
- 230000003110 anti-inflammatory effect Effects 0.000 title description 7
- 239000002981 blocking agent Substances 0.000 title description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 61
- JDZYVVUJIQYGRX-UHFFFAOYSA-N 1-(3-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(F)=C1 JDZYVVUJIQYGRX-UHFFFAOYSA-N 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 24
- 230000001404 mediated effect Effects 0.000 claims abstract description 22
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims abstract description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims abstract description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 60
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 6
- NUUFOILDYXVXLL-UHFFFAOYSA-N 1-(3-methoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC(N2C(C=CC(C)=C2)=O)=C1 NUUFOILDYXVXLL-UHFFFAOYSA-N 0.000 claims description 4
- NDGCMBKTLPWHDG-UHFFFAOYSA-N 5-methyl-1-(3-methylphenyl)pyridin-2-one Chemical compound CC1=CC=CC(N2C(C=CC(C)=C2)=O)=C1 NDGCMBKTLPWHDG-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 3
- MIUCEBJFPNOZFC-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(F)=C1F MIUCEBJFPNOZFC-UHFFFAOYSA-N 0.000 claims description 2
- JFBQYHYEBRHAPT-UHFFFAOYSA-N 1-(2,3-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(C)=C1C JFBQYHYEBRHAPT-UHFFFAOYSA-N 0.000 claims description 2
- DIVMPFRJHNDQHW-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Cl)C=C1Cl DIVMPFRJHNDQHW-UHFFFAOYSA-N 0.000 claims description 2
- ICETYRMEWRWSJX-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(F)C=C1F ICETYRMEWRWSJX-UHFFFAOYSA-N 0.000 claims description 2
- XBUPCRKIBSIBGJ-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC(OC)=CC=C1N1C(=O)C=CC(C)=C1 XBUPCRKIBSIBGJ-UHFFFAOYSA-N 0.000 claims description 2
- PQEYQPAPGLIVEI-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)-5-methylpyridin-2-one Chemical compound CC1=CC(C)=CC=C1N1C(=O)C=CC(C)=C1 PQEYQPAPGLIVEI-UHFFFAOYSA-N 0.000 claims description 2
- IXSFWFDBKAFHHA-UHFFFAOYSA-N 1-(2,5-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Br)=CC=C1Br IXSFWFDBKAFHHA-UHFFFAOYSA-N 0.000 claims description 2
- LUYVIZYIGZWLEK-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Cl)=CC=C1Cl LUYVIZYIGZWLEK-UHFFFAOYSA-N 0.000 claims description 2
- MDXCTWOGPDQWFR-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(F)=CC=C1F MDXCTWOGPDQWFR-UHFFFAOYSA-N 0.000 claims description 2
- IFJQAFSORYKHGW-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=C(OC)C(N2C(C=CC(C)=C2)=O)=C1 IFJQAFSORYKHGW-UHFFFAOYSA-N 0.000 claims description 2
- LVXOEVCZHWSZMZ-UHFFFAOYSA-N 1-(2,5-dimethylphenyl)-5-methylpyridin-2-one Chemical compound CC1=CC=C(C)C(N2C(C=CC(C)=C2)=O)=C1 LVXOEVCZHWSZMZ-UHFFFAOYSA-N 0.000 claims description 2
- ZEICHSKCYQRIIG-UHFFFAOYSA-N 1-(2,6-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(Br)C=CC=C1Br ZEICHSKCYQRIIG-UHFFFAOYSA-N 0.000 claims description 2
- DMZNWOKZNPSKSP-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(Cl)C=CC=C1Cl DMZNWOKZNPSKSP-UHFFFAOYSA-N 0.000 claims description 2
- CXIJPJZPSZHTNT-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(F)C=CC=C1F CXIJPJZPSZHTNT-UHFFFAOYSA-N 0.000 claims description 2
- PIZBPTZVIPMEJT-UHFFFAOYSA-N 1-(2,6-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC(OC)=C1N1C(=O)C=CC(C)=C1 PIZBPTZVIPMEJT-UHFFFAOYSA-N 0.000 claims description 2
- MJWRQZILSOKOTB-UHFFFAOYSA-N 1-(2-methoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC=C1N1C(=O)C=CC(C)=C1 MJWRQZILSOKOTB-UHFFFAOYSA-N 0.000 claims description 2
- PPEKVFBDIFWVEV-UHFFFAOYSA-N 1-(3,4-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Br)C(Br)=C1 PPEKVFBDIFWVEV-UHFFFAOYSA-N 0.000 claims description 2
- ULLQONWBBHUDSX-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Cl)C(Cl)=C1 ULLQONWBBHUDSX-UHFFFAOYSA-N 0.000 claims description 2
- GAHWJIZKEGFRLL-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C=CC(C)=C1 GAHWJIZKEGFRLL-UHFFFAOYSA-N 0.000 claims description 2
- KXSZGLHSEASUBA-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C)C(C)=C1 KXSZGLHSEASUBA-UHFFFAOYSA-N 0.000 claims description 2
- NUFQXKSYNQFJSW-UHFFFAOYSA-N 1-(3,5-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(Br)=CC(Br)=C1 NUFQXKSYNQFJSW-UHFFFAOYSA-N 0.000 claims description 2
- QOXOVUCNQVZUEH-UHFFFAOYSA-N 1-(3-iodophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(I)=C1 QOXOVUCNQVZUEH-UHFFFAOYSA-N 0.000 claims description 2
- NNOLFDHGQTWVGS-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(F)C=C1 NNOLFDHGQTWVGS-UHFFFAOYSA-N 0.000 claims description 2
- HUSOSDHHWHLZRF-UHFFFAOYSA-N 1-(4-iodophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(I)C=C1 HUSOSDHHWHLZRF-UHFFFAOYSA-N 0.000 claims description 2
- CPJBLJUDFSFZEP-UHFFFAOYSA-N 1-[2,3-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(C(F)(F)F)=C1C(F)(F)F CPJBLJUDFSFZEP-UHFFFAOYSA-N 0.000 claims description 2
- NCNYJVDWMNCSPR-UHFFFAOYSA-N 1-[2,5-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(C(F)(F)F)=CC=C1C(F)(F)F NCNYJVDWMNCSPR-UHFFFAOYSA-N 0.000 claims description 2
- QQOSQRFHCXTCMT-UHFFFAOYSA-N 1-[2,6-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(C(F)(F)F)C=CC=C1C(F)(F)F QQOSQRFHCXTCMT-UHFFFAOYSA-N 0.000 claims description 2
- LZWXKBBDHOJVPZ-UHFFFAOYSA-N 1-[3,4-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C(F)(F)F)C(C(F)(F)F)=C1 LZWXKBBDHOJVPZ-UHFFFAOYSA-N 0.000 claims description 2
- JQCDQYWMVOPHJK-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JQCDQYWMVOPHJK-UHFFFAOYSA-N 0.000 claims description 2
- VYXSRCVSKXRDAN-UHFFFAOYSA-N 5-methyl-1-(2-methylphenyl)pyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1C VYXSRCVSKXRDAN-UHFFFAOYSA-N 0.000 claims description 2
- RRHMWKBGPCGEOI-UHFFFAOYSA-N 5-methyl-1-[2-(trifluoromethyl)phenyl]pyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1C(F)(F)F RRHMWKBGPCGEOI-UHFFFAOYSA-N 0.000 claims description 2
- IKTCWTVJVXLKRU-UHFFFAOYSA-N 5-methyl-1-[4-(trifluoromethyl)phenyl]pyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C(F)(F)F)C=C1 IKTCWTVJVXLKRU-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- BMLCFMLMGNOAPP-UHFFFAOYSA-N 1-(2,3-dimethoxyphenyl)-5-methylpyridin-2-one Chemical compound COC1=CC=CC(N2C(C=CC(C)=C2)=O)=C1OC BMLCFMLMGNOAPP-UHFFFAOYSA-N 0.000 claims 1
- BLHHEWJJZFVRNB-UHFFFAOYSA-N 1-(2,4-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Br)C=C1Br BLHHEWJJZFVRNB-UHFFFAOYSA-N 0.000 claims 1
- LNCCSHHBXXNHHJ-UHFFFAOYSA-N 1-(2-fluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1F LNCCSHHBXXNHHJ-UHFFFAOYSA-N 0.000 claims 1
- DCDSWTUVNHBRJZ-UHFFFAOYSA-N 1-(2-iodophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1I DCDSWTUVNHBRJZ-UHFFFAOYSA-N 0.000 claims 1
- SGVKQHZMSAOGLV-UHFFFAOYSA-N 1-(3,5-difluorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(F)=CC(F)=C1 SGVKQHZMSAOGLV-UHFFFAOYSA-N 0.000 claims 1
- DLAIQUGBQRXOBE-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC(C)=CC(C)=C1 DLAIQUGBQRXOBE-UHFFFAOYSA-N 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 23
- 229960003073 pirfenidone Drugs 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 241000700159 Rattus Species 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 15
- 206010003246 arthritis Diseases 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000001243 protein synthesis Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000003510 anti-fibrotic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- MCAAQJLJBILPBZ-UHFFFAOYSA-N 1-(3-bromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(Br)=C1 MCAAQJLJBILPBZ-UHFFFAOYSA-N 0.000 description 3
- MACUBSHVKMSFML-UHFFFAOYSA-N 1-(3-chlorophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(Cl)=C1 MACUBSHVKMSFML-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- IFCIIDXNZSQOPD-UHFFFAOYSA-N 1-(2,3-dibromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC(Br)=C1Br IFCIIDXNZSQOPD-UHFFFAOYSA-N 0.000 description 1
- BHBNMKITFOZDAB-UHFFFAOYSA-N 1-(2,6-dimethylphenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=C(C)C=CC=C1C BHBNMKITFOZDAB-UHFFFAOYSA-N 0.000 description 1
- PYZJZGLJFOVHRH-UHFFFAOYSA-N 1-(4-bromophenyl)-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(Br)C=C1 PYZJZGLJFOVHRH-UHFFFAOYSA-N 0.000 description 1
- WMCCIACZTXJBNZ-UHFFFAOYSA-N 1-[2,4-bis(trifluoromethyl)phenyl]-5-methylpyridin-2-one Chemical compound C1=C(C)C=CC(=O)N1C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WMCCIACZTXJBNZ-UHFFFAOYSA-N 0.000 description 1
- FLYJEBSUJDZJDE-UHFFFAOYSA-N 3-phenyl-1h-pyridin-2-one Chemical class O=C1NC=CC=C1C1=CC=CC=C1 FLYJEBSUJDZJDE-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Definitions
- compositions comprising 5-methyl-1- (substituted phenyl) -2 (IH) -pyridones .
- Inflammation is a common pathological event and inflammatory diseases cover many medical conditions . Inflammatory process is a complex processes. Many mediators have been identified to have roles in the inflammatory process. Certain inflammatory diseases apparently have a central mediator: such as cytokine, tumor necrosis factor-alpha (TNF- ⁇ ) , and therefore these inflammatory diseases are also called TNF- ⁇ mediated diseases: such as rheumatoid arthritis (RA) .
- RA rheumatoid arthritis
- TNF- ⁇ is a 17 kDa, multi-functional peptide produced by a wide variety of cells during host responses to tissue or organ injury including microbial infections and neoplastic diseases.
- Activated macrophages are a major cellular source for TNF- ⁇ , although other cell types, e.g., T cells, mast cells, neutrophils, endothelial cells, and astrocytes, can be stimulated to secrete TNF- ⁇ .
- Enhanced TNF- ⁇ synthesis is associated with the development of numerals inflammatory diseases, such as rheumatoid arthritis (RA) , as well as numerals other inflammatory diseases, such as, psoriasis, psoriatic arthritis, asthma, sepsis, and inflammatory bowel disease (Crohn' s) .
- RA rheumatoid arthritis
- numerals other inflammatory diseases such as, psoriasis, psoriatic arthritis, asthma, sepsis, and inflammatory bowel disease (Crohn' s) .
- Rheumatoid arthritis a systemic disease
- RA a systemic disease
- the severe inflammatory reaction can cause the degeneration of cartilage and erosion of juxta-articular bone.
- TNF- ⁇ is a central in the pathogenesis of RA and a good therapeutic target for pharmacological intervention.
- TNF- ⁇ blockers etanercept (Enbrel) , inflixmab
- Asthma is characterized by the presence of an inflammatory cell infiltrate in the bronchial mucosa consisting of activated mast cells and T cells.
- cytokines are considered to play a pivotal role in this response, particularly interleukin (IL) -4, IL-5, IL- 6, TNF-alpha.
- IL interleukin
- TNF- ⁇ is recognized as an important mediator in many cytokine-dependent inflammatory events and affects immune response and airway inflammation.
- allergen exposure is the major primary cause of asthma, and that the global increases in asthma prevalence are due to increases in exposure to aeroallergens .
- TNF- ⁇ is released in allergic responses from both mast cells and macrophages . Concentrations of TNF- ⁇ in bronchoalveilar lavage fluid from asthma patients are much higher than that of normal healthy person.
- Sepsis also known as systemic inflammatory response syndrome (SIRS)
- SIRS systemic inflammatory response syndrome
- Sepsis can lead to widespread inflammation and blood clotting. Inflammation may result in redness, heat, swelling, pain, and organ dysfunction or failure. Blood clotting during sepsis causes reduced blood flow to limbs and vital organs, and can lead to organ failure or gangrene (damage to tissues) .
- Experimental animal sepsis shock models demonstrated that administration of TNF- ⁇ blocking agents can significantly reduced sepsis-associated death.
- TNF- ⁇ is one the major pre-inflammatory cytokines that triggers sepsis.
- A is an aromatic group.
- These compounds have good anti-inflammatory and analgestic activities and can reduce serum levels of uric acid and glucose.
- U.S. patent 5,310,562 reported anti-fibrotic activity for 5-methyl-1-phenyl-2 (IH) -pyridone (PIRFENIDONE, PFD).
- U.S. patents 5,518,729 and 5,716,632 extended the anti-fibrotic activity to 44 compounds of N-substituted 2 (IH) -pyridone
- the relative position of R groups can be ortho, meta or para.
- the present invention describes anti-TNF- ⁇ effects of compounds in the 5-methyl-l- (substituted phenyl) -2 (IH) -pyridone family.
- a serious representative substituted phenyl pyridones were synthesized according to the process described in Chinese patent ZL02114190.8 , the disclosure of which is incorporated herein by reference.
- pyridones for example, are 5- methyl-1- (3' -fluorophenyl) -2 (IH) -pyridone (AKF-PD), l-(3'- bromophenyl) -5-methyl-2 (IH) -pyridone (AKF-BR) , 1- (3 ' - chlorophenyl) -5-methyl- 2 (IH) -pyridone (AKF-CL), l-(3'- methylphenyl) -5 -methyl-2 (IH) -pyridone (AKF-CH 3 ), and l-(3'- methoxyphenyl) -5 -methyl-2 (IH) -pyridone (AKF-OCH 3 ).
- the present invention provides a use of one or more compound having the general structural formula (structural formula II) , for treating TNF- ⁇ mediated diseases, such as rheumatoid arthritis,
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a 5-methyl-1- (substituted phenyl) -2 (IH) - pyridone having the structural formula II, wherein the compound is present in an amount effective for treating TNF- ⁇ mediated diseases such as rheumatoid arthritis.
- the present invention also provides uses of a composition comprising a 5-methyl-l- (substituted phenyl) -2 (IH) - pyridone having the structural formula II as disclosed herein for treating TNF- ⁇ mediated diseases, such as rheumatoid arthritis .
- FIG. 1 Inhibition of TNF- ⁇ mRNA synthesis in mouse macrophage by AKF-PD and PFD.
- FIG. 2 Inhibition of TNF- ⁇ protein synthesis and secretion in macrophage by AKF-PD.
- FIG. 3 Inhibition of TNF- ⁇ protein synthesis and secretion in macrophage by five compounds of 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone .
- FIG. 4 Reduction of serum level of TNF- ⁇ in rat arthritis model by AKF-PD.
- FIG. 5 Reduction of paw tissue TNF- ⁇ levels in rat arthritis model by AKF-PD.
- anti-TNF- ⁇ mediated diseases means treating diseases, which have TNF- ⁇ as a crucial pathological factor, such as rheumatoid arthritis.
- anti-inflammatory means managing all immune responses, especially local immune response, excluding TNF- ⁇ mediated diseases.
- PIRFENIDONE a 5-methyl-1- (non-substituted phenyl) -2 (IH) - pyridone.
- IH non-substituted phenyl-2
- the compounds can be l-(2'- bromopheny1) -5 -methyl-2 (IH) -pyridone, 1- (3' -bromophenyl) -5- methyl-2 (IH) -pyridone, or 1- (4 ' -bromophenyl) -5-methyl-2 (IH) - pyridone .
- the compounds can be l-(2'- fluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' -fluorophenyl) -5- methyl-2 (IH) -pyridone, or 1- (4' -fluorophenyl) -5-methyl-2 (IH) - pyridone .
- the compounds can be l-(2'- iodophenyl) -5 -methyl-2 (IH) -pyridone, 1- (3' -iodophenyl) -5- methyl-2 (IH) -pyridone, or 1- (4' -iodophenyl) -5-methyl-2 (IH) - pyridone .
- the compounds can be 1- (2' ,3' -dibromophenyl) -5-methyl-2 (IH) -pyridone, l-(2',4'- dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' - dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,6'- dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3 ' , 4 ' - dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,5' - dibromophenyl) -5-methyl-2 (IH) -pyridone, l-(2',3'- dichlorophenyl) -5-methyl-2 (IH) -pyridone,
- the compounds can be 5-methyl-l- (2 ' -trifluoromethylphenyl) -2 (IH) -pyridone, 5- methyl-1- (4' -trifluoromethylphenyl) -2 (IH) -pyridone, 1- (2' , 3' - bis-trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,4' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,4' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,4'
- the compounds can be 5- methyl-1- (2' -methylphenyl) -2 (IH) -pyridone, 5-methyl-l- (3 '- methylphenyl) -2 (IH) -pyridone, 1- (2' ,3' -dimethylphenyl) -5- methyl-2 (IH) -pyridone, 1- (2' ,4' -dimethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 5' -dimethylphenyl) -5 -methyl-2 (IH) -pyridone, 1- (2' ,6' -dimethylphenyl) -5 -methyl-2 (IH) -pyridone, 1- (3' ,4' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, or l-(3',5'- dimethylphenyl) -5-methyl-2 (IH) -pyridone,
- R can be a straight-chain alkyl group, a branch- chain alkyl group, a straight-chain alkoxy group, or a straight-chain halogenated alkyl group.
- the straight-chain alkyl group or branched-chain alkyl group has 1 to about 6 carbons, more preferably with 1-4 carbons.
- the composition comprising one or more of the compounds disclosed herein can be administered at a daily dosage of about 25 mg to about 6,000 mg.
- the composition of the present invention can be administered by standard procedure.
- the composition can be administered through oral, injectable or topical routes.
- the composition of the present invention can be prepared into any appropriate pharmaceutical formulations according to standard techniques.
- the composition can be formulated as solution, tablet, capsules, suppository, inhaler, suspension, gel, cream, or ointment.
- the substituent is a Fluoro at position 3.
- the composition can be formulated and administered according to standard procedures .
- the present invention also provides a composition comprising a 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone in an amount effective for treating TNF- ( mediated diseases, such as rheumatoid arthritis.
- a composition comprising a 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone in an amount effective for treating TNF- ( mediated diseases, such as rheumatoid arthritis.
- R can be a straight-chain alkyl group, a branch-chain alkyl group, a straight-chain alkoxy group, or a straight-chain halogenated alkyl group.
- the straight-chain alkyl group or branched-chain alkyl group has 1 to about 6 carbons, more preferably with 1-4 carbons.
- the amount effective for treating TNF- ⁇ mediated diseases comprises a daily dosage of about 25 mg to about 6,000 mg.
- the amount effective for treating TNF- ⁇ mediated diseases comprises a daily dosage of about 50 mg to about 2,000 mg, more preferably about 100 mg to about 1,000 mg.
- 264.7 RAW cells mouse macrophages
- AKF-PD or pirfenidone (PFD) for 4 hours at the following doses: 0, 10 ⁇ g/ml, 100 ⁇ g/ml, and 500 ⁇ g/ml.
- 264.7 RAW cells are then stimulated by treatment with lipopolysaccharide (LPS, endotoxin) at 5 ng/ml for 15-20 hours .
- LPS lipopolysaccharide
- endotoxin endotoxin
- the cells are then harvested and mRNA is isolated from cells. Expression of TNF- ⁇ mRNA is assayed by a quantitative real time PCR analysis using the TaqMan PCR core reagent kit (Applied Biosysterns) .
- each column with error bar represents the average of triplicate TNF- ⁇ assay results and the standard deviation (SD) .
- SD standard deviation
- AKF-PD and AKF-OCH3 achieved a biggest suppressive effect with
- mice There were total of three groups of rats: normal control (healthy) group, adjuvant/normal saline treated group, and adjuvant/AKF-PD treated group. Each group had 6 rats.
- 500 mg/kg AKF-PD or normal saline were directly administrated by gavage to rats daily from day 2 to day 14 when animals were sacrificed.
- Sera were collected and subjected to TNF- ⁇ ELISA analysis (ChemiKine) .
- AKF-PD prevents development of adjuvant arthritis
- LD 50 was calculated according to Bliss method.
- Acute toxicity LD 50 for 1- (3 ' -fluorophenyl) -5-methyl-2 (IH) -pyridone was 2979.89 mg/kg with a 95% confidence limit of 2402.70-- 3695.73 mg/kg (Table 2).
- LD 50 for PIRFENIDONE was 955.4 mg/kg with a 95% confidence limit of 550.9--1656.7 mg/kg (Table 3).
- Table 3 The results of Table 3 are very close to those reported in the literature: 997.7 mg/kg (U.S. patent 5,310,562) and 1112 mg/kg (Pharmaceutical Care and Research 5:4823 (2005)). These results indicate that the toxicity for AKF-PD is only one third of that of PIRFENIDONE (2978mg/kg vs 955mg/kg) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
The present invention discloses anti-TNF-a activities of compounds in the 5-methyl-1-(substituted phenyl)-2(1H)-pyridone family. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3'-fluorophenyl)-5-methyl-2(1H)-pyridone, AKF-PD. Accordingly, there is provided a method of using one or more 5-methyl-1-(substituted phenyl)-2(1H)-pyridones to treat TNF-a mediated diseases such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (Crohn's).
Description
USES OF 5-METHYL-l-(SUBSTITUTED PHENYL) -2 (IH) -PYRIDONES AS ANTI-INFLAMMATORY AND TNF-alpha-BLOCKING AGENTS
FIELD OF THE INVENTION
[0001] This invention is related to the uses of compositions comprising 5-methyl-1- (substituted phenyl) -2 (IH) -pyridones .
BACKGROUND OF THE INVENTION
[0002] Inflammation is a common pathological event and inflammatory diseases cover many medical conditions . Inflammatory process is a complex processes. Many mediators have been identified to have roles in the inflammatory process. Certain inflammatory diseases apparently have a central mediator: such as cytokine, tumor necrosis factor-alpha (TNF-α) , and therefore these inflammatory diseases are also called TNF-α mediated diseases: such as rheumatoid arthritis (RA) .
[0003] TNF-α is a 17 kDa, multi-functional peptide produced by a wide variety of cells during host responses to tissue or organ injury including microbial infections and neoplastic diseases. Activated macrophages are a major cellular source for TNF-α, although other cell types, e.g., T cells, mast cells, neutrophils, endothelial cells, and astrocytes, can be stimulated to secrete TNF-α. Enhanced TNF-α synthesis is associated with the development of numerals inflammatory diseases, such as rheumatoid arthritis (RA) , as well as numerals other inflammatory diseases, such as, psoriasis, psoriatic arthritis, asthma, sepsis, and inflammatory bowel disease (Crohn' s) .
[0004] Rheumatoid arthritis (RA) , a systemic disease, is characterized by a chronic inflammatory reaction in the synovium of joints. The severe inflammatory reaction can cause the degeneration of cartilage and erosion of juxta-articular bone. Plenty data indicates that TNF-α is a central in the
pathogenesis of RA and a good therapeutic target for pharmacological intervention. Last decade, three high profile protein TNF-α blockers: etanercept (Enbrel) , inflixmab
(Remicade) , adalimumab (Humira) , have been approved by various regulatory agencies. These injectable protein drugs have been remarkably successful, however their limitation have been recognized gradually (Anti-TNF-α therapies: the next generation,
Palladino MA. et al, Nat Rev. Drug Del, 2(9) 736-746, 2003).
Therefore, there are many efforts trying to develop an alternative anti-TNF-α therapy: orally active, small molecule based therapy.
[0005] Asthma is characterized by the presence of an inflammatory cell infiltrate in the bronchial mucosa consisting of activated mast cells and T cells. Several cytokines are considered to play a pivotal role in this response, particularly interleukin (IL) -4, IL-5, IL- 6, TNF-alpha. TNF-α is recognized as an important mediator in many cytokine-dependent inflammatory events and affects immune response and airway inflammation. Recent studies suggest that allergen exposure is the major primary cause of asthma, and that the global increases in asthma prevalence are due to increases in exposure to aeroallergens . It is known that TNF-α is released in allergic responses from both mast cells and macrophages . Concentrations of TNF-α in bronchoalveilar lavage fluid from asthma patients are much higher than that of normal healthy person.
[0006] Sepsis, also known as systemic inflammatory response syndrome (SIRS) , is a serious medical condition caused by the body's response to an infection. Sepsis can lead to widespread inflammation and blood clotting. Inflammation may result in redness, heat, swelling, pain, and organ dysfunction or failure. Blood clotting during sepsis causes reduced blood flow to limbs and vital organs, and can lead to organ failure or gangrene (damage to tissues) . Experimental animal sepsis shock models demonstrated that administration of TNF-α blocking agents can
significantly reduced sepsis-associated death. TNF-α is one the major pre-inflammatory cytokines that triggers sepsis.
[0007] A number of compounds that exhibit anti-inflammatory and anti-fibrotic activities have been described. U.S. patents 3,839,346, 4,052,509, 4,042,699 published a total of 29 compounds with the following pyridone-like formula (structural formula I) :
[0008] U.S. patent 5,310,562 reported anti-fibrotic activity for 5-methyl-1-phenyl-2 (IH) -pyridone (PIRFENIDONE, PFD). U.S. patents 5,518,729 and 5,716,632 extended the anti-fibrotic activity to 44 compounds of N-substituted 2 (IH) -pyridone
(structural formula I) or N-substituted 3 (IH) -pyridone .
[0009] US patent 5,962,478 reported anti-TNF-α activity for pirfenidone and additional 44 closely related compounds.
[00010] A Chinese patent ZL02114190.8 described the identification and synthesis of many new 5-methyl-1-
(substituted phenyl) -2 (IH) -pyridones compounds having the following general structural formula (structural formula II) :
[00011] U.S. patents 5,716,632 and 5,962,478 listed 7 structural formulas of 5-methyl-l- (substituted phenyl) -2 (IH) - pyridone originally described by Gadekar in U.S. patent 4,042,699. For these "substituted phenyl" compounds, Gadekar established a structure-activity relationship that teaches non- substituted phenyl as the compound with the best biological activities. In a US pending patent, we demonstrated that the substituted phenyl compounds having structural formula II, actually, have more desirable anti-fibrotic activity. Thus, it is of interest to determine whether substituted phenyl compounds having structural formula II would have any desirable anti-TNF-α activity.
SUMMARY OF THE INVENTION
[00012] The present invention describes anti-TNF-α effects of compounds in the 5-methyl-l- (substituted phenyl) -2 (IH) -pyridone family. A serious representative substituted phenyl pyridones were synthesized according to the process described in Chinese patent ZL02114190.8 , the disclosure of which is incorporated herein by reference. These pyridones, for example, are 5- methyl-1- (3' -fluorophenyl) -2 (IH) -pyridone (AKF-PD), l-(3'- bromophenyl) -5-methyl-2 (IH) -pyridone (AKF-BR) , 1- (3 ' - chlorophenyl) -5-methyl- 2 (IH) -pyridone (AKF-CL), l-(3'- methylphenyl) -5 -methyl-2 (IH) -pyridone (AKF-CH3), and l-(3'- methoxyphenyl) -5 -methyl-2 (IH) -pyridone (AKF-OCH3). The compounds were tested on mouse macrophages. AKF-PD was further investigated in animal model of rheumatoid arthritis (RA) . The results presented herein demonstrate that 5-methyl-l- (substituted phenyl) -2 (IH) -pyridones can be potentially used for treatment of TNF-α-mediated inflammatory diseases such as rheumatoid arthritis with much less toxic effect.
[00013] In one embodiment, the present invention provides a use of one or more compound having the general structural formula (structural formula II) , for treating TNF-α mediated diseases, such as rheumatoid arthritis,
[00014] The present invention also provides a pharmaceutical composition comprising a 5-methyl-1- (substituted phenyl) -2 (IH) - pyridone having the structural formula II, wherein the compound is present in an amount effective for treating TNF-α mediated diseases such as rheumatoid arthritis.
[00015] The present invention also provides a method of treating TNF-α mediated diseases, e.g., rheumatoid arthritis, comprising the administration of a compound having the structural formula II, wherein n=l and the substituent R is F, i.e AKF-PD.
[0016] The present invention also provides uses of a composition comprising a 5-methyl-l- (substituted phenyl) -2 (IH) - pyridone having the structural formula II as disclosed herein for treating TNF-α mediated diseases, such as rheumatoid arthritis .
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Aforementioned and other features and advantages of this invention will be evident from the following detailed description of preferred embodiments when read in conjunction with the accompanying drawings in which:
FIG. 1: Inhibition of TNF-α mRNA synthesis in mouse macrophage by AKF-PD and PFD.
FIG. 2: Inhibition of TNF-α protein synthesis and secretion in macrophage by AKF-PD. FIG. 3: Inhibition of TNF-α protein synthesis and secretion in macrophage by five compounds of 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone .
FIG. 4 : Reduction of serum level of TNF-α in rat arthritis model by AKF-PD. FIG. 5: Reduction of paw tissue TNF-α levels in rat arthritis model by AKF-PD.
DETAILED DESCRIPTION OF THE INVENTION
[0018] In the present invention, the term "anti-TNF-α mediated diseases" means treating diseases, which have TNF-α as a crucial pathological factor, such as rheumatoid arthritis. The term "anti-inflammatory" means managing all immune responses, especially local immune response, excluding TNF-α mediated diseases.
[0019] It was shown previously that 5 -methyl-1-phenyl-2 (IH) - pyridone (pirfenidone) is the compound with desirable anti-TNF- α and anti-inflammatory activities, which is consistent with Gadekar's structure-activity relationship: non-substituted phenyl is better than substituted phenyl. Thus, it is unexpected to find 5-methyl-1- (substituted phenyl) -2 (IH) - pyridones (structural formula II) , especially AKF-PD exhibit more potent anti-TNF-α and anti-inflammatory activities and much less toxicity than 5 -methyl-1- (non-substituted phenyl) - 2 (IH) -pyridone (pirfenidone) as shown herein.
[0020] Representative examples of 5 -methyl-1- (substituted phenyl) -2 (IH) -pyridones were synthesized according to the process described in Chinese patent ZL02114190.8, the disclosure of which is incorporated herein by reference. These pyridones are 1- (3 ' -fluorophenyl) -5-methyl-2 (IH) -pyridone (AKF-
PD) , 1- (3' -bromophenyl) -5 -methyl-2 (IH) -pyridone (AKF-BR) , 1-
(3' -chlorophenyl) -5-methyl-2 (IH) -pyridone (AKF-CL) , 1- (3' - methylphenyl) -5 -methyl-2 (IH) -pyridone (AKF-CH3) , and 1- (3' - methoxyphenyl) -5-methyl-2 (IH) -pyridone (AKF-OCH3) . It was determined that anti-TNF-α activities of these 5 -methyl-1-
(substituted phenyl) -2 (IH) -pyridone are enhanced compared to
PIRFENIDONE, a 5-methyl-1- (non-substituted phenyl) -2 (IH) - pyridone. Among the above compounds, the most potent one is 1-
(3' -fluorophenyl) -5 -methyl-2 (IH) -pyridone (AKF-PD) . Moreover, the toxicity of 5 -methyl-1- (substituted phenyl) -2 (IH) -pyridone may be drastically decreased. As presented herein, the LD50 for 1- (3 ' -fluorophenyl) -5-methyl-2 (IH) -pyridone is only 30% percent as that of PIRFENIDONE. It is important to note that TNF-α mediated diseases, such as rheumatoid arthritis and dermatitis, such as eczema, are either chronic or recurrent diseases. It is expected that any treatment is going to be a lengthy process, which warrants a long-term pharmacological intervention. Therefore, just like any long-term drug use, it is very desirable for clinical applications to have anti-TNF-α or anti- inflammatory agent drugs with low toxicity.
[0021] Other examples of 5-methyl-1- (substituted phenyl) - 2 (IH) -pyridones (structural formula II) include, but are not limited to, the following compounds:
[0022] When n=l and R=Br, the compounds can be l-(2'- bromopheny1) -5 -methyl-2 (IH) -pyridone, 1- (3' -bromophenyl) -5- methyl-2 (IH) -pyridone, or 1- (4 ' -bromophenyl) -5-methyl-2 (IH) - pyridone .
[0023] When n=l and R=F, the compounds can be l-(2'- fluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' -fluorophenyl) -5- methyl-2 (IH) -pyridone, or 1- (4' -fluorophenyl) -5-methyl-2 (IH) - pyridone .
[0024] When n=l and R=I, the compounds can be l-(2'- iodophenyl) -5 -methyl-2 (IH) -pyridone, 1- (3' -iodophenyl) -5-
methyl-2 (IH) -pyridone, or 1- (4' -iodophenyl) -5-methyl-2 (IH) - pyridone .
[0025] When n=2 and R=F, Br, or Cl, the compounds can be 1- (2' ,3' -dibromophenyl) -5-methyl-2 (IH) -pyridone, l-(2',4'- dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' - dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,6'- dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3 ' , 4 ' - dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,5' - dibromophenyl) -5-methyl-2 (IH) -pyridone, l-(2',3'- dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 4' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (3 ' , 4 ' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, l-(3',5'- dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,3' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2 ' , 4 ' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 5' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' - difluorophenyl) -5-methyl-2 (IH) -pyridone, l-(3',4'- difluorophenyl) -5-methyl-2 (IH) -pyridone, or l-(3',5'- difluorophenyl) -5-methyl-2 (IH) -pyridone.
[0026] When n= 1 or 2 and R= trifluoromethyl, the compounds can be 5-methyl-l- (2 ' -trifluoromethylphenyl) -2 (IH) -pyridone, 5- methyl-1- (4' -trifluoromethylphenyl) -2 (IH) -pyridone, 1- (2' , 3' - bis-trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,4' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,4' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, or 1- (3' , 5' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone.
[0027] When n= 1 or 2 and R= methyl, the compounds can be 5- methyl-1- (2' -methylphenyl) -2 (IH) -pyridone, 5-methyl-l- (3 '- methylphenyl) -2 (IH) -pyridone, 1- (2' ,3' -dimethylphenyl) -5- methyl-2 (IH) -pyridone, 1- (2' ,4' -dimethylphenyl) -5-methyl-2 (IH) -
pyridone, 1- (2' , 5' -dimethylphenyl) -5 -methyl-2 (IH) -pyridone, 1- (2' ,6' -dimethylphenyl) -5 -methyl-2 (IH) -pyridone, 1- (3' ,4' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, or l-(3',5'- dimethylphenyl) -5 -methyl-2 (IH) -pyridone.
[0028] When n= 1 or 2 and R= methoxyl, the compounds can be
1- (2' -methoxyphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' - methoxyphenyl) -5 -methyl -2 (IH) -pyridone, 1- (2' ,3' - dimethoxyphenyl) -5 -methyl-2 ( IH) -pyridone , 1- ( 2 ' , 4 ' - dimethoxyphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 5' - dimethoxyphenyl) -5 -methyl-2 (IH) -pyridone, 1- (2' , 6' - dimethoxyphenyl) -5 -methyl-2 (IH) -pyridone , 1- ( 3 ' , 4 ' - dimethoxyphenyl) -5 -methyl-2 (IH) -pyridone, or l-(3',5'- dimethoxyphenyl) -5 -methyl-2 (IH) -pyridone.
[0029] In one embodiment, the present invention provides a method of treating TNF-α mediated diseases, comprising the step of administrating a composition comprising one or more compound having the general structural formula II as shown above, wherein when n=l, the substituent R can be F, Br, I, a nitro group, an alkyl group, an alkoxy group, or a halogenated alkyl group,- wherein when n=2, the substituent R can be F, Cl, Br, I, an alkyl group, an alkoxy group, or a halogenated alkyl group,- and wherein the relative position of R is ortho, meta or para.. Preferably, when n=l, R is F, Br, or I; when n=2, R is F, Cl, Br, I, alkyl group, alkoxy group, or halogenated alkyl group, for example, R can be a straight-chain alkyl group, a branch- chain alkyl group, a straight-chain alkoxy group, or a straight-chain halogenated alkyl group. In general, the straight-chain alkyl group or branched-chain alkyl group has 1 to about 6 carbons, more preferably with 1-4 carbons.
[0030] According to the method of the present invention, the composition comprising one or more of the compounds disclosed herein can be administered at a daily dosage of about 25 mg to about 6,000 mg. The composition of the present invention can be administered by standard procedure. For example, the composition can be administered through oral, injectable or
topical routes. Similarly, the composition of the present invention can be prepared into any appropriate pharmaceutical formulations according to standard techniques. For example, the composition can be formulated as solution, tablet, capsules, suppository, inhaler, suspension, gel, cream, or ointment.
[0031] In another embodiment, there is provided a method of treating TNF-α mediated diseases, such as rheumatoid arthritis, comprising administering to a subject a composition comprising a 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone having the structural formula II, wherein n=l and the substituent R is F. For example, the substituent is a Fluoro at position 3. The composition can be formulated and administered according to standard procedures .
[0032] The present invention also provides a composition comprising a 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone in an amount effective for treating TNF- ( mediated diseases, such as rheumatoid arthritis. The 5-methyl-1- (substituted phenyl) - 2 (IH) -pyridone has the general structural formula II as shown above, wherein when n=l, the substituent R can be F, Br, I, a nitro group, an alkyl group, an alkoxy group, or a halogenated alkyl group; wherein when n=2, the substituent R can be F, Cl, Br, I, an alkyl group, an alkoxy group, or a halogenated alkyl group; and wherein the relative position of R is ortho, meta or para. Preferably, when n=l, R is F, Br, or I; when n=2, R is F, Cl, Br, I, alkyl group, alkoxy group, or halogenated alkyl group. For example, R can be a straight-chain alkyl group, a branch-chain alkyl group, a straight-chain alkoxy group, or a straight-chain halogenated alkyl group. In general, the straight-chain alkyl group or branched-chain alkyl group has 1 to about 6 carbons, more preferably with 1-4 carbons. In one embodiment, the amount effective for treating TNF-α mediated diseases comprises a daily dosage of about 25 mg to about 6,000 mg. Preferably, the amount effective for treating TNF-α mediated diseases comprises a daily dosage of about 50 mg to about 2,000 mg, more preferably about 100 mg to about 1,000 mg.
[0033] The present invention being generally described, will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
EXAMPLE 1.
Inhibition of TNF-α mRNA synthesis in mouse macrophage by AKF- PD and PFD
[0034] Experimental Design: 264.7 RAW cells, mouse macrophages, are pre-treated with AKF-PD or pirfenidone (PFD) for 4 hours at the following doses: 0, 10 μg/ml, 100 μg/ml, and 500 μg/ml. 264.7 RAW cells are then stimulated by treatment with lipopolysaccharide (LPS, endotoxin) at 5 ng/ml for 15-20 hours . The cells are then harvested and mRNA is isolated from cells. Expression of TNF-α mRNA is assayed by a quantitative real time PCR analysis using the TaqMan PCR core reagent kit (Applied Biosysterns) .
[0035] Results: As shown by Fig.l, both AKF-PD and PFD inhibit LPS-stimulated TNF-α mRNA synthesis in mouse macrophage. Approximately 50% inhibition was reached at the dose of 500 μg/ml. In Fig.l, the mouse TNF-α gene expression in the control non-treated cells was taken as 1 and regarded as control. All the other values were expressed as fold increase of the control. The mouse beta actin gene was used as endogenous control. In Fig.l, each column with error bar represents the mean mRNA level ± SD of duplicate samples. Statistical comparisons for all three AKF doses relative to control indicate p < 0.01; PFD at the doses of 100 and 500 μg/ml relative to control indicate P < 0.01. Similar to PFD, AKF-PD can effectively block LPS induced TNF-α production by macrophages.
EXAMPLE 2 .
Inhibition of TNF-α protein synthesis and secretion in macrophage by AKF-PD
[0036] Experimental Procedure: The effect of AKF-PD on TNF-α protein synthesis and secretion was analyzed in LPS-stimulated murine macrophage-like cell line RAW264.7. Cells were pre- treated with AKF-PD for 4 hours at the following doses: 0, 30 μg/ml, 100 μg/ml, and 300 μg/ml . 264.7 RAW cells were then stimulated by the treatment with lipopolysaccharide (LPS, endotoxin) at 100 ng/ml for 8 hours. Cell lysate was prepared from the harvested cells. Media from the cell culture were collected, concentrated 10-fold. Both cell lysate and media were subjected to ELISA assay (OptEIA™) specific for mouse TNF- α according to the manufacturer's instructions (BD Biosciences) .
[0037] Results: As shown by Fig .2 , treatment of the cells with AKF-PD at the dose of 100 μg/ml resulted in a 64% inhibition of secreted levels of TNF-α. At the dose of 300 μg/ml, AKF-PD achieved a robust 89% inhibition of secreted levels of TNF-α (Fig.2A). AKF-PD also suppressed the cellular levels of TNF-α but with less inhibitory effect, achieving approximately 50% inhibition at dose of 300 μg/ml (Fig.2B). Therefore, the exposure of RAW264.7 cells to AKF-PD exerted a significant and dose-dependent suppression of levels of both cell-associated and secreted TNF-α. In Fig.2, each column with error bar represents the average of triplicate TNF-α assay results and the standard deviation (SD) . Statistical comparisons for AKF-PD treated cells relative to the controls indicate P < 0.001 for secreted levels at all three doses; and P < 0.01 for cellular levels at doses of 100 and 300 μg/ml, respectively.
EXAMPLE 3 .
Inhibition of TNP-α protein synthesis and secretion in macrophage by a serious 5 methyl-1- (substituted phenyl) -2 (IH) - pyridone compounds
[0038] Experimental Procedure: The effect of five compounds of 5 -methyl-1- (substituted phenyl) -2 (IH) -pyridone : 5-methyl-1- (3' -fluorophenyl) -2 (IH) -pyridone (AKF-PD) , 1- (3' -bromophenyl) - 5-methyl-2 (IH) -pyridone (AKF-BR), 1- (3 ' -chlorophenyl) -5-methyl- 2 (IH) -pyridone (AKF-CL), 1- (3 ' -methylphenyl) -5-methyl- 2 (IH) - pyridone (AKF-CH3) , and 1- (3 ' -methoxyphenyl) -5-methyl- 2(1H)- pyridone (AKF-OCH3) on TNF-α protein synthesis and secretion was analyzed in LPS-stimulated murine macrophage-like cell line RAW264.7. Cells were pre-treated with AKF compounds for 4 hours at the dose of 30 μg/ml . 264.7 RAW cells were then stimulated by the treatment with lipopolysaccharide (LPS, endotoxin) at 100 ng/ml for 8 hours. Media from the cell cultures were collected, concentrated 10-fold, and subjected to ELISA assay (OptEIA™) specific for mouse TNF-α according to the manufacturer's instructions (BD Biosciences) .
[0039] Results: As shown by Fig. 3, all 5-methyl-l-
(substituted phenyl) -2 (IH) -pyridone compounds inhibited LPS- stimulated secreted levels of TNF-α. At the dose of 30 μg/ml,
AKF-PD and AKF-OCH3 achieved a biggest suppressive effect with
56% and 63% inhibition of TNF-α production, respectively.
Compounds AKF-CL, AKF-BR, and AKF-CH3 also suppressed, but with less inhibitory effect, on secreted levels of TNF-α. In Fig. 3, each column with error bar represents the average of triplicate
TNF-α assay results and the standard deviation (SD) .
Statistical comparisons for AKFs treated cells relative to the controls indicate P < 0.001 for all treatments.
EXAMPLE 4 .
Reduction of serum level of TNF-α in rat arthritis model by AKF- PD
[0040] Experimental procedure: the effect of AKF-PD on suppression of in vivo TNF-α was evaluated in adjuvant-induced arthritis (AIA) in rat, which is a widely used animal model of human rheumatoid arthritis (RA) . Ten-week old male Lewis rat were used. Complete Freund' s-type adjuvant (CFA) was prepared by suspending heat-killed Mycobacterium butyricum (Difco Laboratories) in incomplete Freund' s adjuvant at 7.5 mg/ml . CFA-induced arthritis was stimulated by injection of 0.1 ml of the CFA emulsion intradermalIy at the base of the tail, as described (Arthritis Rhem 39:1677, 1996). There were total of three groups of rats: normal control (healthy) group, adjuvant/normal saline treated group, and adjuvant/AKF-PD treated group. Each group had 6 rats. To both adjuvant treated groups, 500 mg/kg AKF-PD or normal saline were directly administrated by gavage to rats daily from day 2 to day 14 when animals were sacrificed. Sera were collected and subjected to TNF-α ELISA analysis (ChemiKine) .
[0041] Result: As indicated by Fig 4, animals injected with adjuvant only had significantly higher serum levels of TNF-α than did normal controls (47.9 ng/ml versus 8.1 ng/ml) . Induced arthritis animals treated with AKF-PD had significantly suppressed serum TNF-α levels (12.9 ng/mL) , which are comparable to the level in normal controls (8.1 ng/mL) . In Fig 4, the columns with error bar show the mean and SD of six rats.
EXAMPLE 5.
Reduction of paw tissue TNF-α levels in rat arthritis model by AKF-PD
[0042] Experimental procedure: the procedure for CFA-induced arthritis and AKF-PD treatment is exactly same as the EXAMPLE 4.
Animals were sacrificed at dav 14 following adjuvant and AKF-PD
treatment. The paw tissues were harvested and stored at -80°C. After paw tissues thawed, skin was removed, minced, weighed, and extracted at 40C with 5M urea (100 mg wet weight tissue/5 ml buffer) . The extraction was processed by ammonium sulfate 5 precipitation. The partially purified extracts were then frozen immediately until further analysis . Protein concentration in the paw extracts was measured by Bradford Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA) .
.0 [0043] Results: As shown by Fig.5, similar to what observed in sera (Fig. 4) , AKF-PD treatment significantly suppressed paw levels of TNF-α from 8.1 ng/ml in the arthritis rats to 3.4 ng/ml in AKF-PD treated rats. In Fig. 5, each column with error bar shows the mean and SD of six rats.
L5
EXAMPLE 6.
AKF-PD prevents development of adjuvant arthritis
[0044] We have used adjuvant rat arthritis model to evaluate 20 the effect of systemic administration of AKF-PD on the development of arthritis .
[0045] Experimental procedure: Ten-week old male Lewis rats were treated with complete Freund' s-type adjuvant (CFA) as 5 described in EXAMPLE 4. The rats were treated daily with AKF-PD, 500 mg/kg or normal saline by gavage from day 2 to day 14 when animals were sacrificed. Rats treated with CFA alone usually develop arthritis (swollen paw) within 2-week following the inoculation with adjuvant. 0
[0046] Summarized in Table 1, adjuvant injection resulted in an average of 5 g decrease in body weight while untreated normal animals gained an average of 41 g during the two-week period of the study. Administration of AKF-PD to adjuvant treated rats 5 prevented the loss of body weight and caused an average weight gain of 37 g. All of the control animals treated with adjuvant alone (8/8) developed arthritis 10-14 days following the
inoculation of the adjuvant. None of the animals treated with adjuvant plus AKF-PD developed arthritis (0/8) .
Table 1. Arthritis development frequency and paw diameters
EXAMPLE 7.
Comparison of Acute Toxicity of 5-methyl-1- (3' -fluorophenyl) - 2 (IH) -pyridone (AKF-PD) and PIRFENIDONE
[0047] Experimental procedure: Male and female Kun Ming (KM) mice weighing between 18g-22g were acquired from the animal facility of Hsiang-Ya Medical College, the Central South University. Fifty Kun Ming mice were randomly assigned into 5 groups with 5 male and 5 female mice for each group. The animals went through fasting with a normal water supply before starting drug treatment (either AKF-PD or PIRFENIDONE) . The drug was administrated orally by gavage . The volume of liquid drug was 20ml/kg body weight. The range of dosage for AKF-PD or PFD administrated was from 1071 mg/kg to 6000 mg/kg. The dosage difference between two adjacent doses was 1:0.65 (a dose vs the next lower dose) . All animals were maintained under a regular condition. Acute toxic reaction and death within 14 days of post drug treatment were recorded. Autopsy was performed on all dead animals and visual examination was performed on all organs .
[0048] LD50 was calculated according to Bliss method. Acute toxicity LD50 for 1- (3 ' -fluorophenyl) -5-methyl-2 (IH) -pyridone was 2979.89 mg/kg with a 95% confidence limit of 2402.70--
3695.73 mg/kg (Table 2). LD50 for PIRFENIDONE was 955.4 mg/kg with a 95% confidence limit of 550.9--1656.7 mg/kg (Table 3). The results of Table 3 are very close to those reported in the literature: 997.7 mg/kg (U.S. patent 5,310,562) and 1112 mg/kg (Pharmaceutical Care and Research 5:4823 (2005)). These results indicate that the toxicity for AKF-PD is only one third of that of PIRFENIDONE (2978mg/kg vs 955mg/kg) .
TABLE 2. LD50 of 5-methyl-1- (3' -fluorophenyl) -2 (IH) -pyridone
TABLE 3. LD50 of PIRFENIDONE
Claims
1. Use of compounds, 5-methyl-1- (substituted phenyl) -2 (IH) pyridones having a formula II
2. The use of claim 1, wherein when n=l, the substituent R is selected from the group consisting of F, Br, I, a nitro group, an alkyl group, an alkoxy group, and a halogenated alkyl group,- when n=2, the substituent R is selected from the group consisting of F, Cl, Br, I, an alkyl group, an alkoxy group, and a halogenated alkyl group, and wherein the relative position of R is ortho, meta or para.
3. The use of claim 1 or 2 , wherein n=l or 2, R is selected from the group consisting of straight-chain alkyl group, branch-chain alkyl group, straight-chain alkoxy group, and straight-chain halogenated alkyl group.
4. The use of claim 3, wherein the straight-chain alkyl group or branched-chain alkyl group has 1 to about 6 carbons .
5. The use of claims 1, 2, 3 or 4, wherein the composition include one or more compounds selected from the group consisting of 1- (2 ' -bromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' -bromophenyl) -5-methyl-2 (IH) -pyridone, I- (4' - bromophenyl) -5-methyl-2 (] w) -pyridone, 1- (2 ' -fluorophenyl) - 5-methyl-2 (IH) -pyridone, 1- (3' -fluorophenyl) -5-methyl- 2 (IH) -pyridone, 1- (4 ' -fluorophenyl) -5-methyl-2 (IH) - pyridone, 1- (2' -iodophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' - iodophenyl) -5 -methyl-2 (IH) -pyridone, 1- (4' -iodophenyl) -5- methyl-2 (IH) -pyridone, 1- (2' , 3' -dibromophenyl) -5-methyl- ■ 2 (IH) -pyridone, 1- (2' ,4' -dibromophenyl) -5 -methyl-2 (IH) - pyridone, 1- (2' , 5' -dibromophenyl) -5 -methyl-2 (IH) -pyridone, 1- (2' ,6' -dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,4' - dibromophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,5' - dibromophenyl) -5-methyl-2 (IH) -pyridone, l-(2',3'- dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2 ' , 4 ' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,4' - dichlorophenyl) -5-methyl-2 (IH) -pyridone, l-(3',5'- dichlorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2 ' , 3 ' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,4' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 5' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' - difluorophenyl) -5-methyl-2 (IH) -pyridone, l-(3',4'- difluorophenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,5' - difluorophenyl) -5-methyl-2 (IH) -pyridone, 5-methyl-1- (2' - trifluoromethylphenyl) -2 (IH) -pyridone, 5-methyl-1- (4' - trifluoromethylphenyl) -2 (IH) -pyridone, 1- (2' ,3' -bis- trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, l-(2',4'- bis-trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 5' -bis-trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 6' -bis-trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (3 ' , 4 ' -bis-trifluoromethylphenyl) -5-methyl-2 (IH) -pyridone, or 1- (3' ,5' -bis-trifluoromethylphenyl) -5-methyl-2 (IH) - pyridone, 5-methyl-l- (2' -methylphenyl) -2 (IH) -pyridone, 1- (3' -methylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,3' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,4' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,5' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, l-(2',6'- dimethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,4' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' ,5' - dimethylphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' - methoxyphenyl) -5-methyl-2 (IH) -pyridone, 1- (3' - methoxyphenyl) -5 -methyl-2 (IH) -pyridone , 1- (2 ' , 3 ' - dimethoxyphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,4' - dimethoxyphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' , 5' - dimethoxyphenyl) -5-methyl-2 (IH) -pyridone, 1- (2' ,6' - dimethoxyphenyl) -5 -methyl-2 (IH) -pyridone, 1- (3' ,4' - dimethoxyphenyl) -5-methyl-2 (IH) -pyridone, l-(3',5'- dimethoxyphenyl) -5-methyl-2 (IH) -pyridone.
6. The use of claim 1, wherein the composition is administered at a daily dosage of about 25 mg to about 6,000 mg.
7. The use of claim 1 , wherein the TNF-α mediated diseases are selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, asthma, sepsis, psoriasis, and inflammatory bowel disease (Crohn's) .
8. The use of claim 1, wherein the pharmaceutical composition is in one or more form(s) selected from the group consisting of oral administration, injection, ophthalmic application, and / or topical application.
9. The use of claim 1, wherein the amount of the compounds having the formula II contained in the pharmaceutical composition effective for treating TNF-α-mediated diseases is at a daily dosage of about 25 mg to about 6,000 mg.
10. The use of claim 1, wherein the amount of the compounds having the formula II contained in the pharmaceutical composition effective for treating TNF-α-mediated diseases is at a daily dosage of about 50 mg to about 2000 mg. 11 The use of claim 1, wherein the amount of the compounds having the formula II contained in the pharmaceutical composition effective for treating TNF-α-mediated diseases is at a daily dosage of about 100 mg to about 1000 mg.
12 A use of a low toxic compound, 5-methyl-1- (substituted phenyl) -2 (IH) -pyridone having a formula II,
wherein n=l and the substituent R is F, for the preparation of a pharmaceutical composition for treatment of TNF-α mediated diseases.
13 The use of claim 12, wherein the substituent R is a Fluoro at position 3, i.e 1- (3' -fluorophenyl) -5-methyl-2 (IH) - pyridone .
14 The use of claim 12 or 13, wherein the pharmaceutical composition comprises the effective amount of the compound having the formula II at a daily dosage of about 25 mg to about 6, 000 mg.
15 The use of claim 12 or 13, wherein the pharmaceutical composition comprises the effective amount of the compounds having the formula II at a daily dosage of about 50 mg to about 2000 mg.
16 The use of claim 12 or 13, wherein the pharmaceutical composition comprises the amount effective of the compounds with formula II at a daily dosage of about 100 mg to about 1000 mg. The use of claim 12 or 13, wherein the TNF-α mediated diseases is selected from the group consisting of rheumatoid arthritis (RA), psoriatic arthritis, and inflammatory bowel disease (Crohn's) .
The use of claim 12 or 13, wherein the pharmaceutical composition is in one or more form(s) the group consisting of oral administration, injection, ophthalmic application, and / or topical application.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007800231201A CN101472588A (en) | 2007-04-27 | 2007-04-27 | Application of 5-methyl-1-(substituted phenyl)-2-(1H)pyridone compound as anti-inflammatory drug and α-tumor necrosis factor (TNF-α) blocker |
| PCT/CN2007/001423 WO2008131586A1 (en) | 2007-04-27 | 2007-04-27 | Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2007/001423 WO2008131586A1 (en) | 2007-04-27 | 2007-04-27 | Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008131586A1 true WO2008131586A1 (en) | 2008-11-06 |
Family
ID=39925159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2007/001423 WO2008131586A1 (en) | 2007-04-27 | 2007-04-27 | Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101472588A (en) |
| WO (1) | WO2008131586A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010135470A1 (en) * | 2009-05-19 | 2010-11-25 | Intermune, Inc. | Pifenidone derivatives for treating bronchial asthma |
| EP2251328A4 (en) * | 2008-03-10 | 2011-05-25 | Hec Group | CRYSTALLINE 1- (3-FLUOROPHENYL) -5-METHYL-2- (1H) PYRIDONE, ITS METHODS OF PREPARATION, ITS COMPOSITIONS AND ITS APPLICATIONS |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105130884B (en) * | 2015-07-30 | 2017-09-01 | 四川大学 | 5-methyl-2 (1H) pyridone derivatives and their preparation methods and uses |
| CN105085383B (en) * | 2015-08-19 | 2017-09-01 | 四川大学 | 5-methyl-2 (1H) pyridone derivatives and their preparation methods and uses |
| CN111991393A (en) * | 2019-09-26 | 2020-11-27 | 深圳先进技术研究院 | Application of pirfenidone in the preparation of drugs for preventing and treating rheumatoid arthritis |
| CN113456636A (en) * | 2021-07-09 | 2021-10-01 | 中南大学 | Application of flufenidone in preparation of acute liver injury medicine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042699A (en) * | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| CN1386737A (en) * | 2002-06-11 | 2002-12-25 | 中南大学湘雅医学院 | Antifibrosis pyridinone medicine and its prepaing process |
-
2007
- 2007-04-27 CN CNA2007800231201A patent/CN101472588A/en active Pending
- 2007-04-27 WO PCT/CN2007/001423 patent/WO2008131586A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042699A (en) * | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| CN1386737A (en) * | 2002-06-11 | 2002-12-25 | 中南大学湘雅医学院 | Antifibrosis pyridinone medicine and its prepaing process |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2251328A4 (en) * | 2008-03-10 | 2011-05-25 | Hec Group | CRYSTALLINE 1- (3-FLUOROPHENYL) -5-METHYL-2- (1H) PYRIDONE, ITS METHODS OF PREPARATION, ITS COMPOSITIONS AND ITS APPLICATIONS |
| US8232408B2 (en) | 2008-03-10 | 2012-07-31 | Sunshine Lake Pharma Co., Ltd. | Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1H)pyridone, the preparation methods, compositions and applications thereof |
| WO2010135470A1 (en) * | 2009-05-19 | 2010-11-25 | Intermune, Inc. | Pifenidone derivatives for treating bronchial asthma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101472588A (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3112695C (en) | Composition for treating fibrotic diseases, comprising benzhydryl thioacetamide compound as active ingredient | |
| WO2008131586A1 (en) | Uses of 5-methyl-1-(substituted phenyl)-2(1h)-pyridones as anti-inflammatory and tnf-alpha-blocking agents | |
| KR102714537B1 (en) | Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | |
| JP2003531856A (en) | Phosphate transport inhibitors | |
| JP7520394B2 (en) | Drugs with anti-inflammatory bowel disease activity, preparation method and use thereof | |
| EP3251675B1 (en) | Prevention or treatment of uric acid or gout disease | |
| BRPI0708554A2 (en) | use of an extract of the plant species siphonochilus aethiopicus, composition, and use of a compound | |
| CN110088073B (en) | Methods and compositions for treating atopic dermatitis | |
| JP2010083871A (en) | Medicinal composition containing anti-adenoviral agent | |
| CN118787621A (en) | New application of R-salbutamol in the treatment of inflammatory bowel disease and extraintestinal diseases | |
| KR102394110B1 (en) | Novel compound and uses of the same | |
| CN106632378A (en) | Compound capable of inhibiting mast cell degranulation and preparation method and application thereof | |
| KR101342851B1 (en) | Novel phytosphingosine derivatives and composition for preventing and treating inflammatory skin diseases, autoimmune diseases and hyperkeratotic disorders | |
| CN113679728A (en) | Sulfonamide compound and application thereof in preparing medicine for treating diabetes and complications | |
| WO2020004404A1 (en) | IL-1β INHIBITOR | |
| Wu et al. | 9-Hydroxy-8-oxypalmatine, a novel liver-mediated oxymetabolite of palmatine, alleviates hyperuricemia and kidney inflammation in hyperuricemic mice | |
| CN105503710B (en) | A kind of curcumin analogue of substitution of cyclopropane containing N and its medicinal application | |
| CN102091067A (en) | New application of furocoumarin compound in preparing drug | |
| CN114890938B (en) | Indanone compounds and biotin derivatives thereof, preparation methods and applications | |
| CN108191875B (en) | Compound and its application in preparing medicine for treating immune-related diseases | |
| CN109700807B (en) | Application of compound RH-1402 in the preparation of anti-acute kidney injury drugs | |
| CN108743581B (en) | Application of a kind of epoxy laurolactone | |
| CN119970721A (en) | Application of indoleacetic acid in the preparation of drugs for preventing and/or treating fatty liver and liver fibrosis | |
| CN117304163A (en) | Cyclohexylethanol compound, and preparation method, application and pharmaceutical composition thereof | |
| CN118027006A (en) | 2, 4-Diaminopyrimidine derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200780023120.1 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07720996 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07720996 Country of ref document: EP Kind code of ref document: A1 |